ArticleSurgical endoscopy2026
Derivation and internal validation of the enhanced liver fibrosis (ELF)-based prediction score for advanced liver fibrosis in obese patients undergoing bariatric surgery.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver fibrosis in obese patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is associated with liver-related complications and mortality. While liver biopsy is the gold standard for assessing fibrosis, it is unsuitable for follow-up. Contemporary non-invasive alternatives for detecting fibrosis are insufficient for accurate surgical risk stratification in bariatric patients. We aimed to develop and internally validate a multivariable prediction score using the Enhanced Liver Fibrosis (ELF) test, liver stiffness measurement (LSM), and routine preoperative laboratory tests and compare its performance against established non-invasive tests (NITs).
methodsThis prospective study was conducted at AIIMS, New Delhi, from January 2022 to August 2025. All patients underwent standard preoperative evaluation and investigations, followed by intraoperative liver biopsy for histological assessment. The best multivariable logistic regression model was derived for advanced fibrosis (≥ F3) and internally validated with 2000 bootstrap resamples.
resultsIn a complete-case analysis of 189 patients, with a mean BMI of 46.3 ± 8.2 kg/m
conclusionThis score provides an accurate, non-invasive alternative to liver biopsy for ruling out advanced fibrosis in patients with obesity undergoing bariatric surgery, with potential utility for longitudinal follow-up. External validation is warranted before clinical implementation.
Indexed as
Identifiers
42547632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.